Lopez-Galindo M, Bagán JV. Apixaban and oral implications. J Clin Exp Dent. 2015;7(4):e528-34.

 

doi:10.4317/jced.52470

http://dx.doi.org/doi:10.4317/jced.52470

 

References

1. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. The Lancet. 2012;380(9855):1749-58.
http://dx.doi.org/10.1016/S0140-6736(12)60986-6

PMid:23036896

 

2. Imberti D, Gallerani M, Manfredini R. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J Thromb Thrombolysis. 2012;34(2):208-13.
http://dx.doi.org/10.1007/s11239-012-0716-8
PMid:22466929

 

3. Budovich A, Zargarova O, Nogid A. Role of Apixaban (Eliquis) in the Treatment And Prevention of Thromboembolic Disease. Pharm Ther. 2013;38(4):206-31.

PMid:23785225

 

4. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, MosquedaGarcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476-87.
http://dx.doi.org/10.1111/j.1365-2125.2012.04369.x
PMid:22759198 PMCid:PMC3558798

 

5. Maxwell BD, Tran SB, Chen S, Zhang D, Chen B, Zhang H, et al. The syntheses and in vitro biotransformation studies of [14C] apixaban, a highly potent, selective, efficacious and orally bioavailable inhibitor of blood coagulation Factor Xa. J Labelled Compd Radiopharmaceut. 2011;54(8):418-25.
http://dx.doi.org/10.1002/jlcr.1890

 

6. Briongos Figuero S, García Santos-Gallego C, Badimón JJ. Avances en el tratamiento anticoagulante oral de la fibrilación auricular. Medicina Clínica. 2013;141(11):487-93.
http://dx.doi.org/10.1016/j.medcli.2013.02.015
PMid:23597953

 

7. Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478-92.
http://dx.doi.org/10.1007/s11239-011-0551-3
PMid:21318583 PMCid:PMC3090580

 

8. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908-16.
http://dx.doi.org/10.1111/bcp.12114
PMid:23488672 PMCid:PMC3845314

 

9. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776-86.
http://dx.doi.org/10.1111/bcp.12106
PMid:23451769 PMCid:PMC3853536

 

10. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
http://dx.doi.org/10.1124/dmd.108.023143
PMid:18832478

 

11. Lassen M, Davidson B, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement1. Journal of Thrombosis and Haemostasis. 2007;5(12):2368-75.
http://dx.doi.org/10.1111/j.1538-7836.2007.02764.x
PMid:17868430

 

12. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331-9.
http://dx.doi.org/10.1016/j.ahj.2009.07.035
PMid:20211292

 

13. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV, et al. Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood. PloS one. 2013;8(11):e78696.
http://dx.doi.org/10.1371/journal.pone.0078696
PMid:24244342 PMCid:PMC3823858

 

14. Mingarro-de-León A, Chaveli-López B. Alternative to oral dicoumarin anticoagulants: Considerations in dental care. J Clin Exp Dent. 2013;5(5):e273-8.
http://dx.doi.org/10.4317/jced.51226
PMid:24455094 PMCid:PMC3892260

 

15. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-77.
http://dx.doi.org/10.1056/NEJMoa1110899
PMid:22077144

 

16. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487-98.
http://dx.doi.org/10.1056/NEJMoa1006885
PMid:21175312

 

17. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. The Lancet. 2010;375(9717):807-15.
http://dx.doi.org/10.1016/S0140-6736(09)62125-5

PMid:20206776

 

18. Roser-Jones C, Becker RC. Apixaban: an emerging oral factor Xa inhibitor. J Thromb Thrombolysis. 2010;29(1):141-6.
http://dx.doi.org/10.1007/s11239-009-0421-4
PMid:19921101

 

19. Connolly SJ, Eikelboom J, Joyner C, Diener H, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17.
http://dx.doi.org/10.1056/NEJMoa1007432
PMid:21309657

 

20. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
http://dx.doi.org/10.1056/NEJMoa1107039
PMid:21870978

 

21. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). The Lancet. 1999;353(9162):1386-9.
http://dx.doi.org/10.1016/S0140-6736(98)07534-5

PMid:10227218

 

22. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. The Lancet. 2008;372(9632):31-9.
http://dx.doi.org/10.1016/S0140-6736(08)60880-6

PMid:18582928

 

23. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of Venous ThromboembolismAmerican College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. 2008;133(6_suppl):381S-453S.

PMid:18574271

 

24. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604.
http://dx.doi.org/10.1056/NEJMoa0810773
PMid:19657123

 

25. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708.
http://dx.doi.org/10.1056/NEJMoa1207541
PMid:23216615

 

26. Ogawa H, Goto S, Matsuzaki M, Hiro S, Shima D, APPRAISE-J investigators. Randomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J). Circ J. 2013;77(9):2341-8.
http://dx.doi.org/10.1253/circj.CJ-13-0209
PMid:23748920

 

27. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877-85.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.832139
PMid:19470889

 

28. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365(8):699-708.
http://dx.doi.org/10.1056/NEJMoa1105819
PMid:21780946

 

29. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014;35(4):224-32.
http://dx.doi.org/10.1093/eurheartj/eht445
PMid:24144788

 

30. Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013;166(3):549-58.
http://dx.doi.org/10.1016/j.ahj.2013.05.016
PMid:24016506

 

31. Amin A, Stokes M, Wu N, Gatt E, Makenbaeva D, Wiederkehr D, et al. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation. Journal of medical economics. 2013;16(10):1193-202.
http://dx.doi.org/10.3111/13696998.2013.828064
PMid:23883416

 

32. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial FibrillationInsights From the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;61(22):2274-84.
http://dx.doi.org/10.1016/j.jacc.2012.11.082
PMid:23563134

 

33. Eikelboom JW, Connolly SJ, Gao P, Paolasso E, De Caterina R, Husted S, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. Journal of Stroke and Cerebrovascular Diseases. 2012;21(6):429-35.
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2012.05.007

PMid:22818021

 

34. Harrington AR, Armstrong EP, Nolan PE,Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676-81.
http://dx.doi.org/10.1161/STROKEAHA.111.000402

PMid:23549134

 

35. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol.

2012;110(3):453-60.
http://dx.doi.org/10.1016/j.amjcard.2012.03.049

PMid: 22537354

 

36. Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE Trial. Int J Cardiol. 2013;170(2):215-20.
http://dx.doi.org/10.1016/j.ijcard.2013.10.062

PMid:24192334

 

37. Fakhri HR, Janket SJ, Jackson EA, Baird AE, Dinnocenzo R, Meurman JH. Tutorial in oral antithrombotic therapy: biology and dental implications. Med Oral Patol Oral Cir Bucal. 2013;18(3):e461-72.
http://dx.doi.org/10.4317/medoral.19140
PMid:23524440 PMCid:PMC3668874

 

38. Martin A, Le Bonniec B, Fischer A, Marchand-Leroux C, Gaussem P, Samama C, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168(4):4228-33.
http://dx.doi.org/10.1016/j.ijcard.2013.07.152
PMid:23928345

 

39. van Ryn J, Stangier J, Haertter S, Liesenfeld K, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis & Haemostasis. 2010;103(6):1116-27.
http://dx.doi.org/10.1160/TH09-11-0758
PMid:20352166

 

40. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954-62.
http://dx.doi.org/10.1182/blood-2012-06-415943

PMid:20352166